X4 Pharmaceuticals, Inc.
XFOR
$4.10
$0.030.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -111.48% | -467.43% | -678.36% | 111.32% | 62.98% |
| Total Depreciation and Amortization | 60.43% | 126.84% | 224.88% | 241.81% | 89.98% |
| Total Amortization of Deferred Charges | 1.05% | -4.87% | -12.61% | -13.67% | -7.86% |
| Total Other Non-Cash Items | 93.88% | 96.92% | 98.82% | -657.16% | -3,399.97% |
| Change in Net Operating Assets | -196.30% | -77.83% | -702.35% | -248.24% | 677.62% |
| Cash from Operations | 34.59% | 17.96% | 2.80% | -5.86% | -35.63% |
| Capital Expenditure | -- | 87.19% | 43.64% | -142.73% | -443.33% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 121.64% | 49.04% | 80.86% | -77.03% | -154.23% |
| Cash from Investing | -87.83% | -124.47% | -105.61% | 442.51% | 550.11% |
| Total Debt Issued | -- | -100.00% | -100.00% | -11.11% | -11.11% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 81,065.99% | 36,099.61% | 2,152.34% | -99.57% | -99.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,075.85% | 357.50% | -86.09% | -77.61% | -77.07% |
| Foreign Exchange rate Adjustments | 236.54% | -115.81% | 700.00% | -150.00% | -257.58% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 468.67% | 19.30% | -1,124.42% | 39.00% | -92.16% |